TIGIT and neoplasm: Anti-VEGFR2 antibody1. In vivo;2. Suppressed tumor growth and prolonged survival;3. Decreased the level of TOX;4. Reduced the expression of inhibitory receptors (TIM3, LAG3 and TIGIT);5. Increased IFN-γ and TNF production;